EICHORCondition: Post Traumatic Stress Disorder · Sponsor: Deakin University
Interested? Contact the study team ↓
Posttraumatic stress disorder (PTSD) is a common and debilitating mental illness. Current treatments for PTSD include psychotherapy and antidepressant medications. Many patients are unable to tolerate psychotherapy for PTSD and drop out of it. In addition, its effectiveness is limited. Up to 50 percent of patients who receive psychotherapy do not benefit from it. Antidepressant medications have only small benefits in PTSD. They also have unpleasant side effects that can make patients unwilling to take them. There is an urgent need to develop new treatments for PTSD that work and are well-tolerated. Silexan has the potential to provide an important alternative treatment for PTSD. Silexan is derived from lavender oil. It is taken orally in the form of capsules. It is currently available over-the-counter in 14 countries, including Australia and the United States. Previous research has shown that it is an effective treatment for anxiety disorders, including Generalized Anxiety Disorder. It is also well-tolerated by patients. The only side effects that have been identified so far are mild gastrointestinal symptoms (including burping and breath odour) and these are uncommon. The results of a small pilot study suggest that Silexan may also be effective and well-tolerated in PTSD. The STOP trial is a clinical trial that aims to investigate whether adding Silexan to treatment-as-usual improves PTSD symptoms in adults with PTSD. The trial will recruit 278 participants. Participants w…
This description comes directly from the study's public registry record.
Greg Roebuck, MD · +61 3 9035 4749 · greg.roebuck@unimelb.edu.au
Georgia Parkin, PhD · +61 3 9035 3417 · georgia.parkin@unimelb.edu.au
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Aged 18 years or over. 2. Fluent in English. 3. Meet DSM-5 criteria for PTSD, irrespective of occupation (e.g. first responder, police officer, ex-military or civilian), determined using the Mini International Neuropsychiatric Interview 7.0.2. 4. Have a score on the PTSD Checklist for DSM-5 (PCL-5) equal to or over 33. Exclusion Criteria: 1. Are currently serving in the Australian Defence Force 2. Lifetime history of a psychotic or bipolar disorder, or dissociative identity disorder. 3. Moderate or severe alcohol or other substance use disorder within 3 months of screening. 4. Active suicidal or homicidal ideation. 5. Borderline Personality Disorder (BPD). 6. Acute or unstable medical illness or other significant medical condition, that would make participation in the trial unsafe or inappropriate. 7. Pregnancy, lactation or unwillingness to use an acceptable method of contraception (required for both males and females who are of reproductive potential and sexually active with partners of the opposite sex) through the duration of participants' involvement in the study up to and including week 16. Participants will also be advised not to donate eggs or sperm during the study period. 8. Commencement of a trauma-focussed psychotherapy (including Prolonged Exposure, Cognitive Processing Therapy and Eye Movement Desensitisation and Reprocessing) within 3 months of screening. 9. Commencement or change in dose of psychoactive medications within 4 weeks of screening. 10. Participants will be asked not to initiate psychotherapy or change the dose of psychoactive medications during the course of the study except in clinically urgent circumstances; if this becomes necessary, a decision will be made on a case-by-case basis with regard to retaining the participant or terminating their participation. 11. Severe acquired brain injury. 12. Individual is not eligible for public mental health services due to their visa status in Australia or for any other reason. 13. Any other condition that in the opinion of the research team is likely to make completion of the trial requirements infeasible. 14. Inability to understand or speak English to the extent necessary to give informed consent and complete the trial (researcher or clinician-determined).
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| University of Melbourne | Carlton, Victoria, Australia | Recruiting |
| Deakin University | Geelong, Victoria, Australia | Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Recruiting |
| Ramsay Clinic Albert Road | Melbourne, Victoria, Australia | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06412757